Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FDA Accepts New Drug Application for the Radiopharmaceutical Imaging Kit EVG-001 for NETs

December 13th 2022

The FDA has accepted a new drug application for EVG-001, a kit for the preparation of Gallium-68 DOTATOC injection, a radiopharmaceutical approved for imaging of neuroendocrine tumors using positron emission tomography.

Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent

December 12th 2022

Nicholas Acuna discusses research showing that incidence of liver cancer increases over time in people of Mexican descent living in Los Angeles, the “Latino paradox” in health outcomes, and the next steps for this research.

Budigalimab Plus ABBV-151 Demonstrates Variable Activity Across Locally Advanced or Metastatic Solid Tumors

December 6th 2022

The addition of budigalimab to ABBV-151 was well tolerated and significantly enhanced responses in patients with locally advanced or metastatic solid tumors.

Dr. Zhu on Key Results From the TOPAZ-1 Trial in Biliary Tract Cancer

December 6th 2022

Mojun Zhu, MD, discusses key findings from the phase 3 TOPAZ-1 trial in patients with biliary tract cancer.

Dr. Fonkoua on Determining First-Line Treatment Strategies in HCC

December 5th 2022

Lionel Kankeu Fonkoua, MD, discusses key considerations when selecting a treatment regimen for patients with hepatocellular carcinoma.

Helsinn Birex Pharmaceuticals Withdraws European MAA for Infigratinib for Advanced Cholangiocarcinoma

December 1st 2022

The European marketing authorization application of infigratinib for the treatment of advanced cholangiocarcinoma harboring FGFR2 fusions or rearrangements has been withdrawn by Helsinn Birex Pharmaceuticals.

FDA Grants Fast Track Designation to Pelareorep for Advanced/Metastatic Pancreatic Cancer

December 1st 2022

The FDA has granted a fast track designation to pelareorep for use in combination with atezolizumab, gemcitabine, and nab-paclitaxel for the treatment of patients with advanced or metastatic pancreatic cancer.

Trastuzumab Deruxtecan Demonstrates Promising Clinical Activity in Heavily Pretreated HER2-Low Gastric/GEJ Adenocarcinoma

December 1st 2022

Fam-trastuzumab deruxtecan-nxki induced tumor reduction in more than 60% of patients with HER2-low gastric or gastroesophageal junction adenocarcinoma.

Tremelimumab Plus Durvalumab Receives Go-ahead for Treatment of HCC

November 30th 2022

Ghassan K. Abou-Alfa, MD, discusses the administration of tremelimumab plus durvalumab in hepatocellular carcinoma and where the combination will fit in the treatment paradigm.

NT-I7/Pembrolizumab Combo Shows Clinical Efficacy in MSS CRC and Pancreatic Cancer Without Liver Metastasis

November 30th 2022

The combination of NT-I7 and pembrolizumab showed significant clinical activity in checkpoint inhibitor–naïve, relapsed/refractory microsatellite stable colorectal cancer and pancreatic cancer without liver metastasis.

NICE Recommends Nivolumab/Chemo for HER2- Advanced Stomach and Esophageal Cancer

November 29th 2022

The United Kingdom’s National Institute for Health and Care Excellence has issued final guidance recommending the use of nivolumab plus chemotherapy as a treatment option for patients with HER2-negative advanced stomach and esophageal cancer.

Multidisciplinary Approach Leads to Higher Rate of Neoadjuvant Treatment Completion in Pancreatic Cancer

November 23rd 2022

Patients with localized pancreatic adenocarcinoma who received care at a multidisciplinary clinic had significantly higher neoadjuvant therapy completion rates than those treated at a specialty-specific clinic.

Frontline Pembrolizumab Plus Chemotherapy Meets OS End Point in HER2-Negative Gastric/GEJ Adenocarcinoma

November 22nd 2022

The combination of pembrolizumab and physician’s choice of chemotherapy produced a statistically significant overall survival benefit vs chemotherapy plus placebo in patients with HER2-negative, locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Luminary Awards Honor GI Experts, Patient Advocate

November 18th 2022

OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center, have recognized 4 gastrointestinal physician-scientists and a prominent patient advocate, naming them as 2022 Luminary Awards in GI Cancers.

Zolbetuximab Plus mFOLFOX6 Improves Survival in Claudin 18.2+ Gastric or GEJ Cancers

November 17th 2022

The addition of zolbetuximab to oxaliplatin, leucovorin, and fluorouracil significantly improved progression-free survival vs fluorouracil alone in patients with Claudin 18.2–positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Second-line Fruquintinib Plus Paclitaxel Improves PFS in Chinese Patients With Gastric Cancer

November 15th 2022

The addition of fruquintinib to paclitaxel in the second-line treatment of Chinese patients with advanced gastric or gastroesophageal junction adenocarcinoma significantly improved progression-free survival over paclitaxel alone.

European Commission Recommends Trastuzumab Deruxtecan Approval for Pretreated HER2+ Gastric Cancer

November 14th 2022

The European Medicines Agency’s CHMP has recommended the approval of trastuzumab deruxtecan as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.

Management of Hepatocellular Carcinoma: Future Directions in Care

November 11th 2022

Expert insight to how the field of hepatocellular carcinoma management may evolve in coming years given therapeutic combinations and ongoing clinical trials.

Patient Profile 3: Advanced HCC Treated With Cabozantinib in Second Line

November 11th 2022

Centering discussion on the final patient profile, panelists consider how they select optimal therapy in the second-line setting of advanced hepatocellular carcinoma.

Sequencing Strategies, Improving QOL Are Top Priorities in Neuroendocrine Neoplasm Treatment

November 10th 2022

Diane Reidy-Lagunes, MD, discussed the role of next-generation sequencing paired with systemic therapies and the option of peptide receptor radionuclide therapy in neuroendocrine malignancies.